U01HG012051

Genomic Control of Gene Regulatory Networks Governing Early Human Lineage Decisions - Abstract

Predicting the impact of genomic variation requires quantitative modeling to deconstruct the interplay between multiple individual variants and to determine their combined effects on gene regulatory networks (GRNs) that control cell state and cell function. We focus on the GRNs that control early human development as a paradigm.

Arguably the most important lineage decision during mammalian development is the decision of epiblast cells to exit the pluripotent state (a state when the cells have the potential to give rise to all somatic cells and germ cells) and differentiate into one of the three primary germ layers: the endoderm, mesoderm, and ectoderm. This pluripotent state and the trilineage differentiation can be captured using cultured human embryonic stem cells (hESCs).

Much attention has focused on the GRNs underlying the maintenance of the self-renewing pluripotent state, but the GRNs governing hESC trilineage differentiation remain largely unexplored. We previously conducted genome-scale CRISPR/Cas screens to discover protein-coding genes that regulate the transition of hESCs to definitive endoderm. Based on the genomic and genetic data and machine learning (GKM-SVM sequence analysis), we expanded our initial simple two transcription factor (TF) model to a multiple TF cooperative model.

Here, we propose an integrative approach examining the hESC transition to definitive endoderm, mesoderm, and neuroectoderm germ layer identities to improve the generalizability of GRN models. We will perform quantitative genomic and proteomic measurements with high temporal and single-cell resolution. These quantitative measurements will be combined with perturbation of key GRN elements, core TFs and their target enhancers, to inform the generation of dynamic GRN models.

To further improve the precision of our new GRN models, we will map cell trajectories during state transitions through lineage tracing combined with single-cell RNA sequencing (scRNA-seq). Beyond hESC-guided differentiation, the physiological relevance of enhancers will be further interrogated in human and mouse organoids (gastruloids) and mouse embryos.

We will then apply innovative new computational and algorithmic methods to our multimodal experimental data to generate GRN models, aiming to learn generalizable principles underlying the contribution of genomic variants to cellular and ultimately organismal phenotypes.

Developing GRN models for the exit of pluripotency and the acquisition of germ layer identities involves dynamic modeling of the cell state transition, which will not only inform our understanding of early human development but can also serve as the basis for construction of generalizable GRN models for biological transitions during embryonic development, adult tissue homeostasis and regeneration, as well as inappropriate cell fate transitions that occur in pathological conditions such as cancer.

Sloan-Kettering Institute For Cancer Research

NHGRI SUPPORTS THE DEVELOPMENT OF RESOURCES AND TECHNOLOGIES THAT WILL ACCELERATE GENOME RESEARCH AND ITS APPLICATION TO HUMAN HEALTH AND GENOMIC MEDICINE. A CRITICAL PART OF THE NHGRI MISSION CONTINUES TO BE THE STUDY OF THE ETHICAL, LEGAL AND SOCIAL IMPLICATIONS (ELSI) OF GENOME RESEARCH. NHGRI ALSO SUPPORTS THE TRAINING AND CAREER DEVELOPMENT OF INVESTIGATORS AND THE DISSEMINATION OF GENOME INFORMATION TO THE PUBLIC AND TO HEALTH PROFESSIONALS. THE SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM IS USED TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM IS USED TO FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.172 - Human Genome Research

National Human Genome Research Institute (NHGRI) [HHS - NIH]

New York United States

State-Wide

Defining Genomic Influence on Gene Network Regulation (U01 Clinical Trial Not Allowed) (RFA-HG-20-044)

Amendment Since initial award the End Date has been shortened from 05/31/26 to 05/31/25 and the total obligations have increased 331% from $1,330,000 to $5,732,841.